ETR:EVT - Evotec SE (EVT.F) Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: €30.25
  • Forecasted Upside: 17.52 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
€25.74
▲ +0.34 (1.34%)
1 month | 3 months | 12 months
Get New Evotec SE (EVT.F) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EVT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EVT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
€30.25
▲ +17.52% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Evotec SE (EVT.F) in the last 3 months. The average price target is €30.25, with a high forecast of €33.00 and a low forecast of €28.00. The average price target represents a 17.52% upside from the last price of €25.74.
Buy
The current consensus among 4 contributing investment analysts is to buy stock in Evotec SE (EVT.F). This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/8/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/4/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/2/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/31/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/30/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/29/2020

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
11/20/2020Royal Bank of CanadaSet Price TargetBuy€32.00
i
11/13/2020Deutsche Bank AktiengesellschaftSet Price TargetBuy€28.00
i
11/12/2020Baader BankSet Price TargetBuy€28.00
i
11/12/2020Royal Bank of CanadaSet Price TargetBuy€30.00
i
10/20/2020Baader BankSet Price TargetBuy€28.00
i
10/14/2020Baader BankSet Price TargetBuy€28.00
i
10/13/2020Royal Bank of CanadaSet Price TargetBuy€30.00
i
10/9/2020Deutsche Bank AktiengesellschaftSet Price TargetBuy€28.00
i
10/8/2020Baader BankSet Price TargetBuy€28.00
i
9/9/2020Royal Bank of CanadaSet Price TargetBuy€30.00
i
8/18/2020Baader BankSet Price TargetBuy€28.00
i
7/30/2020Deutsche Bank AktiengesellschaftSet Price TargetBuy€28.00
i
7/21/2020Baader BankSet Price TargetBuy€28.00
i
6/23/2020Baader BankSet Price TargetBuy€28.00
i
6/15/2020Deutsche Bank AktiengesellschaftSet Price TargetBuy€28.00
i
6/9/2020Deutsche Bank AktiengesellschaftSet Price TargetBuy€28.00
i
5/18/2020Deutsche Bank AktiengesellschaftSet Price TargetBuy€28.00
i
5/12/2020Deutsche Bank AktiengesellschaftSet Price TargetBuy€28.00
i
3/27/2020Berenberg BankSet Price TargetBuy€33.00
i
3/27/2020Deutsche Bank AktiengesellschaftSet Price TargetBuy€28.00
i
3/12/2020Deutsche Bank AktiengesellschaftSet Price TargetBuy€28.00
i
1/28/2020Berenberg BankSet Price TargetBuy€33.00
i
1/23/2020Deutsche Bank AktiengesellschaftSet Price TargetBuy€25.00
i
1/16/2020Deutsche Bank AktiengesellschaftSet Price TargetBuy€25.00
i
1/10/2020Deutsche Bank AktiengesellschaftSet Price TargetBuy€25.00
i
12/4/2019Berenberg BankSet Price TargetBuy€28.00
i
11/25/2019Berenberg BankSet Price TargetBuy€28.00
i
11/14/2019Deutsche Bank AktiengesellschaftSet Price TargetBuy€25.00
i
11/12/2019Berenberg BankSet Price TargetBuy€28.00
i
11/8/2019Deutsche Bank AktiengesellschaftSet Price TargetBuy€25.00
i
10/22/2019Deutsche Bank AktiengesellschaftSet Price TargetBuy€25.00
i
9/25/2019Deutsche Bank AktiengesellschaftSet Price TargetBuy€25.00
i
9/12/2019Berenberg BankSet Price TargetBuy€28.00
i
9/5/2019Deutsche Bank AktiengesellschaftSet Price TargetBuy€25.00
i
8/22/2019Deutsche Bank AktiengesellschaftSet Price TargetBuy€25.00
i
8/15/2019Deutsche Bank AktiengesellschaftSet Price TargetNeutral€25.00
i
8/1/2019Berenberg BankSet Price TargetNeutral€28.00
i
5/22/2019Berenberg BankSet Price TargetNeutral€20.00
i
5/17/2019Deutsche Bank AktiengesellschaftSet Price TargetNeutral€23.00
i
5/7/2019Deutsche Bank AktiengesellschaftSet Price TargetNeutral€23.00
i
4/10/2019Deutsche Bank AktiengesellschaftSet Price TargetNeutral€23.00
i
3/5/2019Berenberg BankSet Price TargetNeutral€20.00
i
12/10/2018Deutsche Bank AktiengesellschaftSet Price TargetBuy€22.00
i
11/15/2018Oddo BhfSet Price TargetBuy€26.00
i
11/14/2018Deutsche Bank AktiengesellschaftSet Price TargetBuy€21.00
i
11/8/2018Deutsche Bank AktiengesellschaftSet Price TargetBuy€21.00
i
9/7/2018Berenberg BankSet Price TargetNeutral€20.00
i
9/5/2018Oddo BhfSet Price TargetBuy€26.00
i
8/13/2018Deutsche Bank AktiengesellschaftSet Price TargetBuy€21.00
i
8/10/2018Oddo BhfSet Price TargetBuy€22.00
i
8/9/2018Berenberg BankSet Price TargetNeutral€14.00
i
7/26/2018Oddo BhfSet Price TargetBuy€22.00
i
6/12/2018Oddo BhfSet Price TargetBuy€22.00
i
4/3/2018Deutsche Bank AktiengesellschaftSet Price TargetBuy€20.00
i
3/28/2018Berenberg BankSet Price TargetNeutral€16.00
i
3/8/2018Berenberg BankSet Price TargetNeutral€16.00
i
3/7/2018Oddo BhfSet Price TargetBuy€20.00
i
12/7/2017Berenberg BankSet Price TargetNeutral€16.00
i
12/5/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy€17.00
i
11/29/2017Oddo BhfSet Price TargetBuy€20.00
i
11/9/2017Oddo BhfSet Price TargetBuy€20.00
i
11/8/2017Berenberg BankSet Price TargetNeutral€16.00
i
11/6/2017Deutsche Bank AktiengesellschaftSet Price TargetNeutral€17.00
i
9/19/2017Berenberg BankSet Price TargetNeutral€16.00
i
8/30/2017Deutsche Bank AktiengesellschaftSet Price TargetNeutral€16.00
i
8/21/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy€16.00
i
8/17/2017Berenberg BankSet Price TargetNeutral€16.00
i
8/14/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy€16.00
i
8/11/2017Oddo SecuritiesSet Price TargetNeutral€14.00
i
8/10/2017Berenberg BankSet Price TargetNeutral€13.00
i
8/7/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy€16.00
i
7/31/2017Berenberg BankSet Price TargetNeutral€13.00
i
6/6/2017Berenberg BankSet Price TargetNeutral€13.00
i
5/29/2017Berenberg BankSet Price TargetBuy€9.50
i
(Data available from 11/30/2015 forward)
Evotec SE (EVT.F) logo
Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates in two segments, EVT Execute and EVT Innovate. The EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services. The EVT Innovate segment is involved in investing and developing early-stage discovery programs, as well as advanced drug candidates in the areas of diabetes and diabetic complications, inflammatory diseases, neuroscience, oncology, and pain and anti-infective. Evotec SE has a strategic drug discovery and development partnership with Celgene Corporation; strategic research alliance with Novo Nordisk A/S and Celmatix Inc.; collaboration with Sanofi; research collaboration with Almirall; research alliance with Ferring Pharmaceuticals; strategic collaboration with Centogene; collaboration with Immuneering; drug discovery alliance with LEO Pharma; strategic partnerships with the Sensyne Health plc, Oxford University Innovation Ltd., Secarna Pharmaceuticals GmbH & Co. KG, and Oxford Sciences Innovation to fund LAB10x; and drug discovery and development partnership with Aeovian Pharmaceuticals Inc. The company also has a collaboration with Indivumed GmbH; a partnership with Celmatix Inc.; a strategic collaboration with Ildong Pharmaceutical Co., Ltd.; and a drug discovery research collaboration with HitGen Inc. The company was founded in 1993 and is headquartered in Hamburg, Germany.
Read More

Today's Range

Now: €25.74
€25.28
€25.80

50 Day Range

MA: €23.78
€21.89
€25.42

52 Week Range

Now: €25.74
€17.17
€26.77

Volume

585,780 shs

Average Volume

1,360,000 shs

Market Capitalization

$4.18 billion

P/E Ratio

279.78

Dividend Yield

N/A

Beta

N/A